Company intelligence / Profile preview

Saab

Sioux Falls, South Dakota, United Statessaab.com ↗

Ownership: Private
Development stage: Other

Overview

SAB BIO’s lead candidate, SAB‑142, is a novel disease-modifying immunotherapy designed to delay onset and progression of type 1 diabetes by targeting the autoimmune process that destroys insulin-producing beta cells. Early clinical data across seven trials with related assets show favorable safety and immunogenicity profiles with no serum sickness or neutralizing anti-drug antibodies observed. The company has recently received FDA IND clearance to advance clinical studies in new-onset stage 3 type 1 diabetes.

Therapeutic areas: Endocrinology
Modalities: AntibodyPolyclonal antibodyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Saab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saab.

Explore the full profile